骨粗鬆症治療薬の市場規模、シェア、成長分析：薬剤クラス別、タイプ別、流通チャネル別、地域別 - 産業予測、2024-2031年

骨粗鬆症治療薬の世界市場規模は2022年に71億米ドルと評価され、2023年の73億4,000万米ドルから2031年には95億9,000万米ドルに達し、予測期間（2024-2031年）のCAGRで3.40％の成長が予測されています。

世界の骨粗鬆症治療薬市場は、特に高齢化社会における骨粗鬆症の有病率の増加を主因として、力強い成長を遂げています。この慢性疾患は骨密度の低下と骨折リスクの高まりを特徴とするため、早期診断とタイムリーな治療オプションの重要性に対する認識が急増しています。このような意識の高まりに加え、革新的な治療法や標的ドラッグデリバリーシステムなど、骨粗鬆症治療開発の著しい進歩が、市場の拡大をさらに後押ししています。とはいえ、骨粗鬆症治療薬に関連する高額な費用や長期使用による副作用の可能性といった課題が、市場拡大の障害となっています。こうした障害にもかかわらず、効果的で安全な骨粗鬆症治療薬への需要が高まっていることから、今後数年間は市場の勢いが持続すると予想されます。具体的には、米国の骨粗鬆症治療薬市場は、次の予測期間中も安定した年間平均成長率（CAGR）を維持すると予想され、これは、この蔓延する健康上の懸念に対処し、治療法の改善と利用しやすさの向上を通じて患者の転帰を改善するという継続的な取り組みを反映しています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ分析
• PESTEL分析
• 規制情勢
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度

骨粗鬆症治療薬市場：薬剤クラス別

• 市場概要
• ブランド医薬品
• ジェネリック医薬品

骨粗鬆症治療薬市場：タイプ別

• 市場概要
• ビスフォスフォネート
• 副甲状腺ホルモン
• カルシトニン
• 選択的エストロゲン阻害薬モジュレーター
• ランクリガンド阻害剤
• その他

骨粗鬆症治療薬市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

骨粗鬆症治療薬市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Amgen Inc.（US）
• Eli Lilly and Company（US）
• Merck & Co., Inc.（US）
• Novartis International AG（Switzerland）
• Pfizer Inc.（US）
• GlaxoSmithKline plc（UK）
• Radius Health, Inc.（US）
• UCB S.A.（Belgium）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（US）
• Sanofi S.A.（France）
• AbbVie Inc.（US）
• AstraZeneca PLC（UK）
• Hologic, Inc.（US）
• Lundbeck A/S（Denmark）
• Eisai Co., Ltd.（Japan）
• Ferring Pharmaceuticals（Switzerland）
• Sandoz International GmbH（Switzerland）
• Servier Laboratories（France）
• Bayer AG（Germany）
• Grunenthal GmbH（Germany）

Global Osteoporosis Drugs Market size was valued at USD 7.1 billion in 2022 and is poised to grow from USD 7.34 billion in 2023 to USD 9.59 billion by 2031, growing at a CAGR of 3.40% during the forecast period (2024-2031).

The global osteoporosis drugs market is witnessing robust growth, primarily driven by the increasing prevalence of osteoporosis, particularly among the aging population. As this chronic condition is characterized by diminished bone density and heightened risk of fractures, there has been a surge in awareness regarding the importance of early diagnosis and timely treatment options. This heightened awareness, coupled with significant advancements in the development of osteoporosis treatments-such as innovative therapies and targeted drug delivery systems-has further propelled the market's expansion. Nevertheless, challenges such as the high costs associated with osteoporosis medications and potential side effects from long-term usage pose hurdles to market progress. Despite these obstacles, the escalating demand for both effective and safe osteoporosis treatments is anticipated to sustain market momentum in the coming years. Specifically, the U.S. osteoporosis drugs market is expected to maintain a steady compound annual growth rate (CAGR) during the next forecast period, reflecting the ongoing commitment to addressing this prevalent health concern and improving patient outcomes through improved therapies and increased accessibility.

Top-down and bottom-up approaches were used to estimate and validate the size of the global osteoporosis drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global osteoporosis drugs Market Segmental Analysis

Global Osteoporosis Drugs Market is segmented by Drug Class, Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Branded, and Generic. Based on Type, the market is segmented into Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator, Rank Ligand Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the global osteoporosis drugs Market

The burgeoning aging population worldwide serves as a significant market driver for the global osteoporosis drugs market. As life expectancy rises, the incidence of osteoporosis increases, resulting in heightened demand for effective treatment solutions. This demographic shift is compounded by growing awareness of bone health, leading to more frequent diagnoses of osteoporosis and, consequently, a greater need for therapeutic options. Moreover, continuous advancements in pharmaceutical research, including the development of innovative drugs with enhanced efficacy and safety profiles, are further propelling market growth. Together, these factors create a robust environment for expanding osteoporosis treatment options globally.

Restraints in the global osteoporosis drugs Market

A significant restraint in the global osteoporosis drugs market is the high cost of treatment, which often poses a barrier to patient access and adherence. Osteoporosis management typically necessitates prolonged medication and continuous monitoring, leading to substantial financial burdens, particularly for individuals in low-income or developing areas. The exorbitant prices of branded medications, coupled with inadequate insurance coverage for osteoporosis therapies, create accessibility challenges for patients. This financial strain may deter potential users from seeking or maintaining necessary treatments, thereby restricting the overall adoption of osteoporosis drugs and stifling market growth, especially in regions with limited healthcare resources and affordability issues.

Market Trends of the global osteoporosis drugs Market

A prominent trend in the global osteoporosis drugs market is the surge in research and development aimed at innovative therapies that demonstrate enhanced efficacy and safety. With the rising global incidence of osteoporosis, pharmaceutical companies are prioritizing the creation of cutting-edge treatments that not only effectively manage the disease but also minimize fracture risks. This trend is fueled by advancements in biotechnology and novel drug delivery systems, allowing the formulation of targeted, personalized therapies. As patient-centric approaches gain traction, the market is witnessing an emergence of convenient delivery methods that align with the evolving needs of osteoporosis management, setting a transformative trajectory for the industry.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• PESTEL Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Osteoporosis Drugs Market by Drug Class

• Market Overview
• Branded
• Generic

Osteoporosis Drugs Market by Type

• Market Overview
• Bisphosphonates
• Parathyroid Hormone
• Calcitonin
• Selective Estrogen Inhibitor Modulator
• Rank Ligand Inhibitor
• Others

Osteoporosis Drugs Market by Distribution Channel

• Market Overview
• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy

Osteoporosis Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radius Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Servier Laboratories (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments